Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891443 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
A Phase 3 study of Eye Diseases and Retinal Disease, sponsored by Laboratoires Thea.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 14
- Study locations
NCT06891443: Recruiting Phase 3 study of Eye Diseases and Retinal Disease, sponsored by Laboratoires Thea.
NCT06891443 is a Phase 3 study of Eye Diseases and Retinal Disease that is actively recruiting participants, run by Laboratoires Thea. The registered enrollment target is 32 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06891443, a Phase 3 study of Eye Diseases and Retinal Disease, is actively recruiting participants, sponsored by Laboratoires Thea.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
Primary Outcome
Change from baseline in BCVA based on the Freiburg Acuity and Contrast Test (FrACT) between Treatment Eyes (TEs) and Placebo Control Eyes (PCEs)
Conditions Studied
Interventions
- DRUG sepofarsen
- OTHER Placebo IVT
Study Locations (14)
Other
- Universitair Ziekenhuis Gent (UZ) - Ghent
- Centre de maladies rares CHNO des Quinze Vingt - Paris
- Justus-Liebig Universität - Department of Ophthalmology - Giessen
- Klinikum der Ludwig-Maximilian Universität München - München
- University of Tuebingen - Inst. for Ophthalmic Research - Tübingen
- Radboud Universitair Medisch Centrum - Nijmegen
- Moorfields Eye Hospital NHS Foundation Trust - London
California
- UCSF Wayne and Gladys Valley Center for Vision - San Francisco
Florida
- University of Miami - Bascom Palmer Eye Institute - Miami
Iowa
- University of Iowa - Iowa City
Minnesota
- University of Minnesota Medical School - Minneapolis
Pennsylvania
- University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics - Philadelphia
Alberta
- University of Alberta - Edmonton
Ontario
- The Hospital for Sick Children - SickKids - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
What NCT06891443 shows while recruiting
NCT06891443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which sepofarsen is the first listed.
NCT06891443 lists 14 locations in 8 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06891443 about?
NCT06891443 is a clinical study titled "Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)". The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
What is the current status of trial NCT06891443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-06-04. Estimated completion is 2028-10.
What conditions does trial NCT06891443 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Eye Diseases, Hereditary, Blindness, Sensation Disorders.
What interventions are being tested in trial NCT06891443?
The interventions under investigation include: sepofarsen (DRUG), Placebo IVT (OTHER).
Who is sponsoring clinical trial NCT06891443?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891443 being conducted?
This trial has 14 study locations across California, Florida, Iowa, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06891443's enrollment target sits among peer trials
32 21st of 27 higher than 7 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI